Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Krisztina Bogos1, Szilvia Török1, Mariann Pucsok1

  • 1Országos Korányi Pulmonológiai Intézet, Budapest, Hungary. bogos@koranyi.hu.

Magyar Onkologia
|March 28, 2022
PubMed
Summary

Patients with lung cancer face higher COVID-19 risks but can receive adequate care through healthcare adjustments and vaccination. COVID-19 vaccines are safe and recommended, including booster doses, for lung cancer patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cancer Diagnoses and Deaths in Hungary, 2011-2023: Nationwide Trends Before, During, and After the COVID-19 Pandemic.

Cancers·2026
Same author

Immune-related markers define clinically relevant prognostic subgroups in thymic epithelial tumors.

Lung cancer (Amsterdam, Netherlands)·2026
Same author

MiR-21 Is a Novel Diagnostic and Prognostic Circulating Biomarker in Pleural Mesothelioma.

Diagnostics (Basel, Switzerland)·2026
Same author

Targeting P2RY2 reprograms tumor immunity and inhibits tumor growth in non-small cell lung cancer.

Cancer letters·2026
Same author

[Could the administration of immune checkpoint inhibitors be discontinued after 2 years of application? Pros and cons for the development of a national guideline.]

Magyar onkologia·2026
Same author

Reactive Oxygen Species Drive Cell Migration and PD-L1 Expression via YB-1 Phosphorylation in Pleural Mesothelioma.

Antioxidants (Basel, Switzerland)·2026

Area of Science:

  • Oncology
  • Infectious Diseases
  • Public Health

Background:

  • The COVID-19 pandemic significantly impacted global healthcare systems.
  • Cancer patients, especially those with lung malignancies, are a high-risk group for severe COVID-19 outcomes.
  • Healthcare system adaptations and improved vaccination were crucial for maintaining oncological care.

Purpose of the Study:

  • To analyze COVID-19 characteristics in patients with thoracic malignancies.
  • To identify determinants for predicting COVID-19 outcomes in this population.
  • To assess the safety and efficacy of COVID-19 vaccines in lung cancer patients.

Main Methods:

  • Review of recent studies on COVID-19 in thoracic malignancy patients.
  • Identification of clinical and biological factors associated with disease severity.
  • Analysis of vaccination data, including booster dose recommendations.

Main Results:

  • Several factors predict COVID-19 outcomes: ECOG performance status, C-reactive protein, neutrophils, procalcitonin levels, disease stage, and pneumonia presence.
  • Personalized therapeutic strategies are being developed based on these findings.
  • COVID-19 vaccines demonstrate safety in lung cancer patients.

Conclusions:

  • Healthcare system restructuring and vaccination efforts have enabled continuity of care for cancer patients during the pandemic.
  • Understanding COVID-19's impact on thoracic malignancies aids personalized treatment.
  • Booster doses are recommended for optimal immunization in lung cancer patients.

Related Experiment Videos